BACKGROUND AND OBJECTIVES: An increasing number of patients are returning to dialysis after allograft loss (DAGL). These patients are at a higher mortality risk compared with incident ESRD patients. Among transplant-naïve patients, those treated with peritoneal dialysis (PD) enjoy an early survival advantage compared with those treated with hemodialysis (HD), but this advantage is not sustained over time. Whether a similar time-dependent survival advantage exists for PD-treated patients after allograft loss is unclear and may impact dialysis modality selection in these patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We identified 2110 adult patients who initiated dialysis after renal transplant failure between January 1991 and December 2005 from The Canadian Organ Replacement Register. Multivariable regression analysis was used to evaluate the impact of initial dialysis modality on early (2 years), late (after 2 years), and overall mortality using an intention-to-treat approach. RESULTS: After adjustment, there was no difference in overall survival between HD- and PD-treated patients (hazard ratio((HD:PD)), 1.05; 95% confidence interval, 0.85 to 1.31), with similar results seen for both early and late survival. Superior survival was seen in more contemporary cohorts of patients returning to DAGL. CONCLUSIONS: The use of PD compared with HD is associated with similar early and overall survival among patients initiating DAGL. Differences in both patient characteristics and predialysis management between patients returning to DAGL and transplant-naive incident dialysis patients may be responsible for the absence of an early survival advantage with the use of PD in DAGL patients.
BACKGROUND AND OBJECTIVES: An increasing number of patients are returning to dialysis after allograft loss (DAGL). These patients are at a higher mortality risk compared with incident ESRDpatients. Among transplant-naïve patients, those treated with peritoneal dialysis (PD) enjoy an early survival advantage compared with those treated with hemodialysis (HD), but this advantage is not sustained over time. Whether a similar time-dependent survival advantage exists for PD-treated patients after allograft loss is unclear and may impact dialysis modality selection in these patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We identified 2110 adult patients who initiated dialysis after renal transplant failure between January 1991 and December 2005 from The Canadian Organ Replacement Register. Multivariable regression analysis was used to evaluate the impact of initial dialysis modality on early (2 years), late (after 2 years), and overall mortality using an intention-to-treat approach. RESULTS: After adjustment, there was no difference in overall survival between HD- and PD-treated patients (hazard ratio((HD:PD)), 1.05; 95% confidence interval, 0.85 to 1.31), with similar results seen for both early and late survival. Superior survival was seen in more contemporary cohorts of patients returning to DAGL. CONCLUSIONS: The use of PD compared with HD is associated with similar early and overall survival among patients initiating DAGL. Differences in both patient characteristics and predialysis management between patients returning to DAGL and transplant-naive incident dialysis patients may be responsible for the absence of an early survival advantage with the use of PD in DAGLpatients.
Authors: Louise M Moist; Friedrich K Port; Sean M Orzol; Eric W Young; Truls Ostbye; Robert A Wolfe; Tempie Hulbert-Shearon; Camille A Jones; Wendy E Bloembergen Journal: J Am Soc Nephrol Date: 2000-03 Impact factor: 10.121
Authors: Dana C Miskulin; Klemens B Meyer; Nicolaos V Athienites; Alice A Martin; Norma Terrin; Jane V Marsh; Nancy E Fink; Josef Coresh; Neil R Powe; Mike J Klag; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-02 Impact factor: 8.860
Authors: R A Wolfe; V B Ashby; E L Milford; A O Ojo; R E Ettenger; L Y Agodoa; P J Held; F K Port Journal: N Engl J Med Date: 1999-12-02 Impact factor: 91.245
Authors: Herwig-Ulf Meier-Kriesche; Akinlolu O Ojo; Friedrich K Port; Julie A Arndorfer; Diane M Cibrik; Bruce Kaplan Journal: J Am Soc Nephrol Date: 2001-06 Impact factor: 10.121
Authors: S W Murphy; R N Foley; B J Barrett; G M Kent; J Morgan; P Barré; P Campbell; A Fine; M B Goldstein; S P Handa; K K Jindal; A Levin; H Mandin; N Muirhead; R M Richardson; P S Parfrey Journal: Kidney Int Date: 2000-04 Impact factor: 10.612
Authors: Ekamol Tantisattamo; Ramy M Hanna; Uttam G Reddy; Hirohito Ichii; Donald C Dafoe; Gabriel M Danovitch; Kamyar Kalantar-Zadeh Journal: Curr Opin Nephrol Hypertens Date: 2020-01 Impact factor: 3.416